万孚生物
(300482)
| 流通市值：90.90亿 | | | 总市值：101.68亿 |
| 流通股本：4.30亿 | | | 总股本：4.81亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 800,275,782.51 | 3,064,809,396.66 | 2,181,361,474.64 | 1,575,250,376.82 |
| 营业收入 | 800,275,782.51 | 3,064,809,396.66 | 2,181,361,474.64 | 1,575,250,376.82 |
| 二、营业总成本 | 588,132,685.22 | 2,433,963,779.68 | 1,715,728,355.95 | 1,184,260,271.92 |
| 营业成本 | 266,703,767.01 | 1,098,880,165.75 | 797,669,919.04 | 561,696,946.09 |
| 税金及附加 | 3,616,536.27 | 15,493,769.11 | 7,250,386.23 | 5,168,221.37 |
| 销售费用 | 158,971,793.4 | 683,498,956.43 | 472,005,966.72 | 318,499,085.16 |
| 管理费用 | 52,419,623.44 | 222,355,215.48 | 153,220,061.93 | 107,384,846.46 |
| 研发费用 | 103,101,058.36 | 411,516,186.87 | 271,181,881.59 | 197,310,702.68 |
| 财务费用 | 3,319,906.74 | 2,219,486.04 | 14,400,140.44 | -5,799,529.84 |
| 其中:利息费用 | 7,532,510.22 | 30,472,622.07 | 21,634,826.15 | 15,086,854.98 |
| 其中:利息收入 | 1,884,531.79 | 18,607,357.64 | 16,320,029.41 | 13,177,444.85 |
| 加:公允价值变动收益 | 11,431,121.13 | 29,617,794.26 | 24,424,625.34 | 15,572,505.9 |
| 加:投资收益 | -406,776.11 | 1,920,270.34 | 1,964,002.7 | -1,211,510.64 |
| 资产处置收益 | - | 759,635.83 | 736,983.24 | - |
| 资产减值损失(新) | -102,886.4 | -12,403,263.34 | - | - |
| 信用减值损失(新) | -12,118,014.68 | -38,763,502.17 | -18,095,942.9 | -15,273,933.05 |
| 其他收益 | 4,659,609.86 | 24,868,736.28 | 23,445,130.67 | 17,143,589.22 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 215,606,151.09 | 636,845,288.18 | 498,107,917.74 | 407,220,756.33 |
| 加:营业外收入 | 516,021.33 | 1,463,959.23 | 1,072,523.02 | 705,826.29 |
| 减:营业外支出 | 1,104,366.31 | 8,846,637.25 | 6,344,520.16 | 2,580,756.36 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 215,017,806.11 | 629,462,610.16 | 492,835,920.6 | 405,345,826.26 |
| 减:所得税费用 | 24,945,584.07 | 64,247,476.36 | 53,019,650 | 47,031,076.2 |
| 六、净利润 | 190,072,222.04 | 565,215,133.8 | 439,816,270.6 | 358,314,750.06 |
| 持续经营净利润 | 190,072,222.04 | 565,215,133.8 | 439,816,270.6 | 358,314,750.06 |
| 归属于母公司股东的净利润 | 189,135,410.14 | 561,628,533.81 | 435,935,866.11 | 355,800,226.55 |
| 少数股东损益 | 936,811.9 | 3,586,599.99 | 3,880,404.49 | 2,514,523.51 |
| (一)基本每股收益 | 0.39 | 1.21 | 0.94 | 0.78 |
| (二)稀释每股收益 | 0.39 | 1.21 | 0.94 | 0.78 |
| 八、其他综合收益 | -27,967.44 | -27,150,639.65 | -222,870.57 | 736,513.98 |
| 归属于母公司股东的其他综合收益 | -27,967.44 | -27,150,639.65 | -222,870.57 | 736,513.98 |
| 九、综合收益总额 | 190,044,254.6 | 538,064,494.15 | 439,593,400.03 | 359,051,264.04 |
| 归属于母公司股东的综合收益总额 | 189,107,442.7 | 534,477,894.16 | 435,712,995.54 | 356,536,740.53 |
| 归属于少数股东的综合收益总额 | 936,811.9 | 3,586,599.99 | 3,880,404.49 | 2,514,523.51 |
| 公告日期 | 2025-04-25 | 2025-04-10 | 2024-10-25 | 2024-08-14 |
| 审计意见(境内) | | 标准无保留意见 | | |